Journal
MOVEMENT DISORDERS
Volume 25, Issue 12, Pages 1818-1822Publisher
WILEY-LISS
DOI: 10.1002/mds.23191
Keywords
calcium channel blockers; Parkinson's disease; antihypertensive
Categories
Funding
- NIH/NINDS [R01 NS048517]
- National Institute of Environmental Health Sciences
- National Institute of Health [Z01ES101986]
- National Institute of Health/National Research Service [T32 ES016645-01]
- NHI/NINDS [R01 NS062879-01A2]
- National Institute of Environmental Health Sciences, NIH [Z01ES101986]
- Department of Defense/USAMRAA
- RJG Foundation
- Fox Foundation
- American Parkinson's Disease Association
- Parkinson's Disease Foundation
- The Parkinson Study Group
- University of Rochester
- Harvard University
- DoD (Department of the Army) [W81XWH-05-1-0117
- 20052009]
Ask authors/readers for more resources
We investigated whether the use of calcium channel blockers (CCBs) was associated with a reduced risk of Parkinson's disease (PD) in two large prospective cohorts: the Nurses' Health Study (NHS) and Health Professionals' Follow- Up Study (HPFS). Cox proportional hazards models were used to estimate relative risks (RRs) and 95% confidence intervals (CIs) to assess the association between use of CCBs and risk of PD adjusting for potential confounders. We identified 514 incident cases of PD during follow-up. No association between baseline use of CCBs (RR 5 1.18, 95% CI: 0.731.92), frequency of use or duration of use of CCBs and PD risk was observed (P > 0.2 for all). These findings do not support a role for CCBs in providing neuroprotection against development of PD. (C) 2010 Movement Disorder Society
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
